摘要
目的:探究参麦注射液联合欣维宁治疗对急性心肌梗死介入后心脏结构和功能的影响。方法:选取我院2012-10-2015-12接收的经皮冠状动脉介入治疗的急性心肌梗死患者120例,按照随机数字法分为对照组60例和观察组60例,2组患者均进行皮冠状动脉介入治疗,对照组患者给予单一欣维宁治疗,观察组患者在此基础上联合参麦注射液治疗,比较2组患者的心脏结构和功能差异。结果:术后4h,观察组患者ST段回降(3.0±0.6)mm,明显高于对照组患者ST段回降(2.5±0.5)mm,差异有统计学意义(t=4.96,P=0.00)。术后7d,观察组患者ST段回降(3.2±0.8)mm,明显高于对照组患者ST段回降(2.7±0.4)mm,差异有统计学意义(t=4.33,P=0.00)。术后半年,观察组患者的左室射血分数(LVEF)、左室舒张末期容积(LVEDV)、收缩末期容积(LVESV)的心功能指标分别为明显优于对照组,差异有统计学意义(P<0.05)。术后半年内,观察组患者不良情况发生率为3.33%(2/60),明显低于对照组患者不良情况发生率18.33(11/60),差异有统计学意义(χ2=5.52,P=0.02)。结论:参麦注射液联合欣维宁治疗可以明显提高急性心肌梗死介入后患者的临床疗效,对其心脏结构和功能都有积极影响,患者的长期预后明显得到改善,故该联合治疗方案值得在临床推广。
Objective：To investigate the influence on cardiac structure and function of patients with acute myocardial infarction treated with Shenmai combined with tirofiban after interventional.Method：Selected 120 cases with acute myocardial infarction treated by percutaneous coronary intervention in our hospital from October 2012 to December 2015 as the research object.According to the random number method,divided them into observation group（60cases）and control group（60cases）.Two groups of patients were performed with percutaneous coronary intervention.Patients in the control group were treated with single tirofiban treatment.Patients in the observation group were treated with Shenmai injection treatment on the base of tirofiban treatment.Compared differences of two groups of patients with cardiac structure and function.Result：Four hours after surgery,the ST falling distance of the observation group was（3.0±0.6）mm,which was significantly higher than the ST falling distance of the control group（2.5±0.5）mm,the difference was significant（t=4.96,P=0.00）.7days after surgery,the ST falling distance of the observation group was（3.2±0.8）mm,which was significantly higher than the ST falling distance of the control group（2.7±0.4）mm,the difference was significant（t=4.33,P=0.00）.Half a year after operation,left ventricular ejection fraction（LVEF）,left ventricular end diastolic volume（LVEDV）,end systolic volume（LVESV）of the observation group were significantly better than that of the control group,the difference was significant（P〈0.05）.Within half a year after the operation,the incidence of adverse circumstances of the observation group was 3.33%（2/60）,which was significantly lower than the incidence of adverse circumstances of the control group 18.33 %（11/60）,the difference was significant（χ2=5.52,P=0.02）.Conclusion：Shenmai injection combined with tirofiban treatment can obviously improve clinical curative effect of patients with acute myocardial infarction（AMI）after intervention,and also has a positive impact on the cardiac structure and function,the long-term prognosis of patients were improved significantly,so the combination therapy is worthy of clinical promotion.
出处
《临床急诊杂志》
CAS
2016年第9期671-674,共4页
Journal of Clinical Emergency
关键词
参麦注射液
欣维宁
经皮冠状动脉介入治疗
急性心肌梗死
Shenmai injection
tirofiban
percutaneous coronary intervention
acute myocardial infarction
